Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
Cummings, Jeffrey Zweifel, M Smith, N Ross, P Peters, J Rustin, G Price, Patricia M Middleton, M R Ward, Timothy H
Cummings, Jeffrey
Zweifel, M
Smith, N
Ross, P
Peters, J
Rustin, G
Price, Patricia M
Middleton, M R
Ward, Timothy H
Citations
Altmetric:
Abstract
OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h.
Description
Date
2012-05-22
Publisher
Collections
Keywords
Type
Article
Citation
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. 2012, 106 (11):1766-71 Br J Cancer